Ex-J&J exec Warren Wang to head up Boston's Chinese operations
This article was originally published in Clinica
Boston Scientific has appointed Warren Wang vice-president and managing director of its operations in China; Mr Wang was previously general manager of Johnson & Johnson's orthopaedic business in the country. He worked for J&J for over 10 years. In his new role, Mr Wang will be based at Boston's Chinese headquarters in Shanghai where he will be responsible for leading the company to "accelerated growth and further market expansion in China". Like many medtech companies, Natick, Massachusetts-based Boston is seeing higher growth outside its domestic market, particularly in emerging economies such as China. During its first fiscal quarter it posted a 4% decline in US sales, at $978m; but "inter-continental" revenues rose 10% to $205m. Overall, the firm's revenues fell 3% to $1.87bn, but this was nonetheless higher than analyst expectations (www.clinica.co.uk, 20 April 2012).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.